Fig. 3From: A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancerMaximum intensity projection images of 64Cu-NOTA-Trastuzumab PET at 1, 24, and 48 h after injectionBack to article page